These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 8739553)

  • 21. Respiratory dysrhythmias in patients with tardive dyskinesia.
    Wilcox PG; Bassett A; Jones B; Fleetham JA
    Chest; 1994 Jan; 105(1):203-7. PubMed ID: 7903923
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early course of new-onset tardive dyskinesia in older patients.
    Lacro JP; Gilbert PL; Paulsen JS; Fell R; Bailey A; Juels C; Caligiuri M; McAdams LA; Harris MJ; Jeste DV
    Psychopharmacol Bull; 1994; 30(2):187-91. PubMed ID: 7831454
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study.
    Morgenstern H; Glazer WM
    Arch Gen Psychiatry; 1993 Sep; 50(9):723-33. PubMed ID: 8102845
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A prospective study of tardive dyskinesia development: preliminary results.
    Kane JM; Woerner M; Weinhold P; Wegner J; Kinon B
    J Clin Psychopharmacol; 1982 Oct; 2(5):345-9. PubMed ID: 6127353
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ten-year outcome of tardive dyskinesia.
    Gardos G; Casey DE; Cole JO; Perenyi A; Kocsis E; Arato M; Samson JA; Conley C
    Am J Psychiatry; 1994 Jun; 151(6):836-41. PubMed ID: 7910437
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Functional analysis of tardive dyskinesia: implications for assessment and treatment.
    Valdovinos MG; Roberts C; Kennedy CH
    J Appl Behav Anal; 2005; 38(2):239-42. PubMed ID: 16033170
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Withdrawal-emergent dyskinesia in patients with schizophrenia during antipsychotic discontinuation.
    Schultz SK; Miller DD; Arndt S; Ziebell S; Gupta S; Andreasen NC
    Biol Psychiatry; 1995 Dec; 38(11):713-9. PubMed ID: 8580223
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol.
    Beasley CM; Dellva MA; Tamura RN; Morgenstern H; Glazer WM; Ferguson K; Tollefson GD
    Br J Psychiatry; 1999 Jan; 174():23-30. PubMed ID: 10211147
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacologic characterization of tardive dyskinesia.
    Lieberman J; Pollack S; Lesser M; Kane J
    J Clin Psychopharmacol; 1988 Aug; 8(4):254-60. PubMed ID: 3209717
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder.
    Correll CU; Josiassen RC; Liang GS; Burke J; O'Brien CF
    Psychopharmacol Bull; 2017 Aug; 47(3):53-60. PubMed ID: 28839340
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia.
    Tsai G; Goff DC; Chang RW; Flood J; Baer L; Coyle JT
    Am J Psychiatry; 1998 Sep; 155(9):1207-13. PubMed ID: 9734544
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Anderson KE; Stamler D; Davis MD; Factor SA; Hauser RA; Isojärvi J; Jarskog LF; Jimenez-Shahed J; Kumar R; McEvoy JP; Ochudlo S; Ondo WG; Fernandez HH
    Lancet Psychiatry; 2017 Aug; 4(8):595-604. PubMed ID: 28668671
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tardive dyskinesia exacerbated after ingestion of phenylalanine by schizophrenic patients.
    Mosnik DM; Spring B; Rogers K; Baruah S
    Neuropsychopharmacology; 1997 Feb; 16(2):136-46. PubMed ID: 9015796
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study.
    Bai YM; Yu SC; Lin CC
    J Clin Psychiatry; 2003 Nov; 64(11):1342-8. PubMed ID: 14658949
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder.
    Kane JM; Correll CU; Liang GS; Burke J; O'Brien CF
    Psychopharmacol Bull; 2017 Aug; 47(3):69-76. PubMed ID: 28839342
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Electrophysiological and pharmacological analysis of L-dopa-induced dyskinesia and tardive dyskinesia (author's transl)].
    Bathien N; Rondot P; Koutlidis RM
    J Physiol (Paris); 1981 Apr; 77(1):131-41. PubMed ID: 6112268
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Heterogeneity of tardive dyskinesia. A multivariate analysis.
    Glazer WM; Morgenstern H; Niedzwiecki D; Hughes J
    Br J Psychiatry; 1988 Feb; 152():253-9. PubMed ID: 3262396
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Masking of tardive dyskinesia with four times-a-day administration of chlorpromazine.
    Jeste DV; Olgiati SG; Ghali AY
    Dis Nerv Syst; 1977 Sep; 38(9):755-8. PubMed ID: 902564
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tardive dyskinesia and positive and negative symptoms of schizophrenia. A study using instrumental measures.
    Yuen O; Caligiuri MP; Williams R; Dickson RA
    Br J Psychiatry; 1996 Jun; 168(6):702-8. PubMed ID: 8773812
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Accelerometric assessment of tardive dyskinesia.
    Tryon WW; Pologe B
    Am J Psychiatry; 1987 Dec; 144(12):1584-7. PubMed ID: 2891307
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.